| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/27/2023 | 1637.97% | HC Wainwright & Co. | → $65 | Reiterates | Buy → Buy |
| 05/16/2023 | 1637.97% | HC Wainwright & Co. | → $65 | Reiterates | Buy → Buy |
| 01/10/2023 | 1637.97% | HC Wainwright & Co. | $6 → $65 | Maintains | Buy |
What is the target price for Biora Therapeutics (BIOR)?
The latest price target for Biora Therapeutics (NASDAQ: BIOR) was reported by HC Wainwright & Co. on July 27, 2023. The analyst firm set a price target for $65.00 expecting BIOR to rise to within 12 months (a possible 1637.97% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biora Therapeutics (BIOR)?
The latest analyst rating for Biora Therapeutics (NASDAQ: BIOR) was provided by HC Wainwright & Co., and Biora Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Biora Therapeutics (BIOR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biora Therapeutics was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.
Is the Analyst Rating Biora Therapeutics (BIOR) correct?
While ratings are subjective and will change, the latest Biora Therapeutics (BIOR) rating was a reiterated with a price target of $0.00 to $65.00. The current price Biora Therapeutics (BIOR) is trading at is $3.74, which is within the analyst's predicted range.